Significant Improvement in DCR by
Independent Central Review
Reck M, et al.
Lancet Oncol
. 2014;15:143-55.
Best response, n (%)
Adenocarcinoma
All Patients
Nintedanib +
docetaxel
(n=322)
Placebo +
docetaxel
(n=336)
Nintedanib +
docetaxel
(n=655)
Placebo +
docetaxel
(n=659)
Complete response (CR)
0
0
0
1 (0.2)
Partial response (PR)
15 (4.7)
12 (3.6)
29 (4.4)
21 (3.2)
Stable disease (SD)
179 (55.6)
136 (40.5)
325 (49.6)
250 (37.9)
Disease control rate
*
(CR + PR + SD)
194
(60.2)
148 (44.0)
354
(54.0)
272 (41.3)
Progressive disease (PD)
87 (27.0)
147 (43.8)
200 (30.5)
298 (45.2)
*
Significant improvement in disease control rate with nintedanib + docetaxel
(
Odds ratio
1.93
;
P
<0.0001 for adenocarcinoma
and
Odds ratio
1.68,
P
<0.0001 for
all patients
)
